Key terms

About ABUS

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ABUS news

Mar 25 4:55am ET Arbutus Biopharma management to meet virtually with JMP Securities Mar 20 5:20pm ET Arbutus Biopharma management to meet virtually with JMP Securities Mar 08 8:07am ET Arbutus Biopharma Showcases at Investor Conferences Mar 05 1:23am ET Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT) Mar 01 6:26am ET Arbutus Biopharma price target lowered to $5 from $6 at H.C. Wainwright Feb 29 1:55pm ET Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects Feb 29 8:19am ET Arbutus Biopharma Anticipates Key 2024 Milestones Feb 29 7:33am ET Arbutus Biopharma reports FY23 EPS (44c), consensus (45c) Feb 12 11:09am ET Biotech Alert: Searches spiking for these stocks today Feb 08 1:05pm ET Jefferies ‘encouraged thus far’ by Arbutus patent hearing Feb 01 11:24am ET Biotech Alert: Searches spiking for these stocks today Jan 29 4:35pm ET Chardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS) Jan 11 6:15am ET Optimistic Outlook for Arbutus Biopharma Amid Anticipated Positive Data and Strategic Pipeline Developments Jan 09 8:55pm ET Arbutus Biopharma: A Buy Rating on Strong Financial Footing and Promising Clinical Prospects Jan 08 7:56am ET Arbutus Biopharma lays out 2024 objectives, sees cash runway into Q1 of 2026

No recent news articles are available for ABUS

No recent press releases are available for ABUS

ABUS Financials

1-year income & revenue

Key terms

ABUS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ABUS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms